Almotriptan: pharmacological differences and clinical results

Area of Science:

• Pharmacology
• Neurology
• Gastroenterology

Background:

• Migraine is a debilitating neurological disorder.
• Selective 5-HT(1B/D) agonists are effective for acute migraine treatment.
• Almotriptan is a novel agent in this class.

Purpose of the Study:

• To review the basic and clinical data of almotriptan.
• To evaluate its efficacy, tolerability, and pharmacokinetic profile.
• To position almotriptan for migraine symptom management.

Main Methods:

• Review of existing pharmacokinetic and clinical trial data.
• Analysis of efficacy and tolerability compared to placebo and sumatriptan.
• Assessment of safety profile, including adverse events.

Main Results:

• Almotriptan exhibits high oral bioavailability (>2/3 absorbed within 1 hour).
• Pharmacokinetics are unaffected by gender or food; metabolism is clean with no significant drug interactions.
• 12.5 mg dose shows efficacy comparable to sumatriptan 100 mg, with low recurrence and placebo-like tolerability.
• Low incidence of chest symptoms (<1%); contraindicated in ischemic cardiomyopathy.

Conclusions:

• Almotriptan possesses a favorable pharmacokinetic and safety profile.
• It offers a good efficacy/tolerability ratio for migraine symptom relief.
• Almotriptan is a strong candidate for migraine treatment.